Form 4: Aprea Therapeutics Director Receives Equity Grant

Director John B. Henneman III was granted restricted stock units and stock options as part of board compensation.

Summary

• Director John B. Henneman III acquired 3,135 restricted stock units (RSUs) on June 16, 2026.
• The director was also granted 12,555 stock options with an exercise price of $0.7293.
• Both the RSUs and the stock options are scheduled to vest on June 16, 2027, contingent upon continued board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of board expertise through standard vesting schedules.

Negatives

• Minor dilution of existing shareholders due to the issuance of new equity and options.

Risks

• Vesting is subject to continued service on the board, creating potential turnover risk if the director departs before June 16, 2027.

Future Outlook

The filing does not provide forward-looking business guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is standard practice in the biotechnology sector to ensure long-term alignment between leadership and corporate performance.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard corporate governance practices for small-cap biotech firms.
• The grant size is typical for non-executive director compensation packages in the industry.

Corporate Governance

Stakeholder Impact

• Shareholders experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of equity awards on June 16, 2027.

Key Dates

Keywords

Aprea Therapeutics, APRE, Form 4, Insider Trading, Director Compensation, Equity Grant